scholarly journals Choose Wisely: Metered Dose Inhalers Versus Nebulized Inhaled Solutions in The Inpatient Setting

2021 ◽  
Vol 67 (4) ◽  
pp. 13-16
Author(s):  
Meera Alshamali ◽  
Robin Lee ◽  
Alice Change ◽  
Johnny Wong
Keyword(s):  
Drug Cost ◽  
Medical Center ◽  
Cost Savings ◽  
Secondary Outcome ◽  
Inpatient Setting ◽  
Metered Dose Inhalers ◽  
Implementation Phase ◽  
Medication Waste ◽  
Hospitalization Costs ◽  
Metered Dose

Background Healthcare expenditures continue to rise, and hospitalization costs remain the driving factor for nationally increasing health expenditures.(1,3) Affordability initiatives targeted at minimizing inpatient drug spending and medication waste are vital. Metered dose-inhalers (MDIs) impose high potential for medication waste as their bulk nature provides a day supply that far exceeds average hospitalization length of stay.(1,7) Kaiser Permanente Baldwin Park Medical Center inpatient pharmacy adopted a cost saving initiative aimed at converting the commonly prescribed ipratropium MDI to its equivalent nebulized solution. Methods This was a retrospective medication use evaluation (MUE), assessing the overall drug cost impact of converting patients from ipratropium MDI to ipratropium nebulized solution. The study period consisted of two phases: the pre-implementation phase from 11/1/2017 to 09/30/2018, and the post-implementation phase from 11/01/2018 to 09/30/2019.The study population consisted of patients admitted to the Critical Care Unit (CCU) and Step-Down Unit (SDU), who were prescribed an ipratropium MDI or ipratropium nebulized solution. Patients who were under the age of 18 years old were excluded. The primary outcome was to analyze the drug cost savings of prescribing nebulized solutions over MDIs in the inpatient setting. The secondary outcome was to assess overall compliance with the conversion protocol. Results Ipratropium MDI administrations declined by 91% (from 3,751 to 336) during the post-implementation phase. An estimated drug cost savings of $68,700 occurred by converting the ipratropium MDIs to ipratropium nebulized solution. Conclusion This conversion protocol was successful at reducing MDI waste and attaining substantial drug cost savings at our medical center over a period of 1 year since implementation.

Economic Evaluation of a Pharmacist-Led 5-Day Therapeutic Hold of IV Levothyroxine at an Academic Medical Center

2020 ◽  
pp. 001857872097045
Author(s):  
Blake T. Barlow ◽  
Russel J. Roberts ◽  
Kelly Newman ◽  
Sarah K. Harrison ◽  
Jonathan H. Sin
Keyword(s):  
Medical Center ◽  
Financial Burden ◽  
Academic Medical Center ◽  
Cost Savings ◽  
Surgical Trauma ◽  
Implementation Phase ◽  
Academic Medical ◽  
Pharmacokinetic Properties ◽  
Utilization Data ◽  
Surgical Icu

Objective: Providers often admit patients with active outpatient prescriptions for levothyroxine. During an inpatient admission, providers may instruct critically ill patients to take nothing by mouth, or nil per os (NPO). Thus, they may prescribe the intravenous (IV) formulation of levothyroxine during this period. However, levothyroxine possesses a prolonged half-life of up to 7 days; therefore, immediate transition to IV levothyroxine may not be clinically necessary in the acute NPO setting. Intravenous levothyroxine is significantly more expensive than equivalent oral doses and may prove to be a financial burden for an institution. By understanding the pharmacokinetic properties of levothyroxine, we implemented a cost-saving initiative involving a 5-day therapeutic hold of IV levothyroxine. Methods: This was a retrospective evaluation in 2 intensive care units (ICU): a 20-bed surgical/trauma ICU and an 18-bed mixed medical/surgical ICU. Patient data, utilization data, and documented pharmacist interventions were collected for 6 months prior to implementation of the 5-day IV levothyroxine therapeutic hold and for 6 months post-implementation. All patients prescribed IV levothyroxine during these timeframes were included. Results: During the 6-month pre-implementation phase, 674 doses (691 vials) of IV levothyroxine for 77 unique patients were dispensed from the 2 ICUs. During the 6-month post-implementation phase, 168 doses (188 vials) of IV levothyroxine were dispensed for 44 unique patients. Of the 44 patients (48 orders) who still received IV levothyroxine, 22.9% of orders were deemed clinically necessary by the pharmacist and were not recommended to be held under the protocol, 64.6% were due to the verifying pharmacist being unaware of the protocol, 8.3% of orders were due to protocol non-compliance, and 4.2% were verified after the 5-day hold was complete as the patient remained NPO. This pharmacy-led initiative resulted in a 75% decrease in usage post-implementation and an estimated annualized savings of $80,000. Conclusion: A pharmacy-led initiative comprised of a 5-day therapeutic hold of IV levothyroxine was feasible and led to a 75% reduction in usage and cost over a 6-month period in 2 ICU’s. Future steps include additional staff education for improved protocol adherence and expanding the protocol institution-wide for an even greater cost-savings potential.

scholarly journals 47. Transitioning to Batch Dosing of High-Cost Antimicrobials in the Inpatient Setting

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S144-S144
Author(s):  
Matthew Lokant ◽  
Shu Xian Lee ◽  
Connor Nevin ◽  
John D Lindsay ◽  
Colby Acri ◽  
...  
Keyword(s):  
Cost Savings ◽  
Early Morning ◽  
Inpatient Setting ◽  
Antimicrobial Use ◽  
Medication Waste ◽  
Antimicrobial Utilization ◽  
Early Afternoon ◽  
Medication Dosage ◽  
Specific Formulation ◽  
Appropriate Antimicrobial Use

Abstract Background Antimicrobial stewardship (AMS) committees ensure appropriate antimicrobial utilization. One stewardship intervention is to evaluate the delivery model of high-cost antimicrobials to better utilize resources and mitigate expenses. We analyzed the total medication waste and costs of high-cost antimicrobials, specifically daptomycin, ertapenem, amphotericin, and micafungin, at our institution and propose innovative cost-savings changes at a systems level. Methods This retrospective study consisted of 263 patients. All patients were at least 18 years old who was admitted to our academic institution from January 2020 to April 2021 and received daptomycin, ertapenem, amphotericin, or micafungin. Demographics, daily medication dosage, total doses received, the date and time of the start of the medication, last administered dose, and discontinued order were recorded. Results The daptomycin cohort consisted of 143 patients with 46.2% females and average age of 56.3 years. In this group, 145.3 vials were wasted which equated to a loss of &22,630. The ertapenem group had 53 patients with 62.3% females and a mean age of 62.3 years. There were 24 vials wasted with a calculated loss of &1080. The amphotericin cohort had 32 patients with an average age of 52.2 years and 43.8% females. There were 189 vials wasted with a loss of &46,116. The micafungin group had 35 patients with 42.9% females and average age of 60.4 years. This group had 12 vials wasted with a loss of &2052. Conclusion Each antimicrobial has a specific formulation protocol. Daptomycin and ertapenem formulation occurs in the early morning. Amphotericin formulation occurs 2 hours prior to medication use. Micafungin formulation occurs at the time the order label prints. These medications were more often administered in the late morning to early afternoon timeframe. The order to discontinue the medications also occurred at the same interval. One reason could be due to decisions made on morning rounds from primary teams and specialty input. These orders would then be placed after rounds. A cost-saving method would be to batch and change the formulation time for all antimicrobials to later in the afternoon, which would not only prevent waste, but also allow the AMS team to effectively audit appropriate antimicrobial use. Disclosures All Authors: No reported disclosures

scholarly journals Cost effectiveness analysis of implementing tuberculosis screening among applicants for non-immigrant U.S. work visas

Pneumonia ◽  
2020 ◽  
Vol 12 (1) ◽  
Author(s):  
Bisma Ali Sayed ◽  
Drew L. Posey ◽  
Brian Maskery ◽  
La’Marcus T. Wingate ◽  
Martin S. Cetron
Keyword(s):  
United States ◽  
Home Country ◽  
Screening Program ◽  
Cost Savings ◽  
The United States ◽  
Active Tuberculosis ◽  
Multiple Perspectives ◽  
Tuberculosis Screening ◽  
Hospitalization Costs ◽  
The U.S

Abstract Background While persons who receive immigrant and refugee visas are screened for active tuberculosis before admission into the United States, nonimmigrant visa applicants (NIVs) are not routinely screened and may enter the United States with infectious tuberculosis. Objectives We evaluated the costs and benefits of expanding pre-departure tuberculosis screening requirements to a subset of NIVs who arrive from a moderate (Mexico) or high (India) incidence tuberculosis country with temporary work visas. Methods We developed a decision tree model to evaluate the program costs and estimate the numbers of active tuberculosis cases that may be diagnosed in the United States in two scenarios: 1) “Screening”: screening and treatment for tuberculosis among NIVs in their home country with recommended U.S. follow-up for NIVs at elevated risk of active tuberculosis; and, 2) “No Screening” in their home country so that cases would be diagnosed passively and treatment occurs after entry into the United States. Costs were assessed from multiple perspectives, including multinational and U.S.-only perspectives. Results Under “Screening” versus “No Screening”, an estimated 179 active tuberculosis cases and 119 hospitalizations would be averted in the United States annually via predeparture treatment. From the U.S.-only perspective, this program would result in annual net cost savings of about $3.75 million. However, rom the multinational perspective, the screening program would cost $151,388 per U.S. case averted for Indian NIVs and $221,088 per U.S. case averted for Mexican NIVs. Conclusion From the U.S.-only perspective, the screening program would result in substantial cost savings in the form of reduced treatment and hospitalization costs. NIVs would incur increased pre-departure screening and treatment costs.

Evaluation of Cost-effectiveness and Clinical Value of Routine Histopathologic Examination of Septoplasty Specimens

2021 ◽  
pp. 019459982110129
Author(s):  
Randall S. Ruffner ◽  
Jessica W. Scordino
Keyword(s):  
Chart Review ◽  
Medical Center ◽  
Academic Medical Center ◽  
Cost Savings ◽  
Retrospective Chart Review ◽  
Clinical Value ◽  
Level Of Evidence ◽  
Significant Pathology ◽  
National Model ◽  
Routine Histopathologic Examination

Objectives During septoplasty, normal cartilage and bone are often sent for pathologic examination despite benign appearance. We explored pathology results following septoplasty from April 2016 to April 2018, examining clinical value and relevance, implications, and cost analysis. Study Design Retrospective chart review. Setting Single-institution academic medical center. Methods A retrospective chart review was compiled by using Current Procedural Terminology code 30520 for septoplasty for indication of nasal obstruction, deviated septum, and nasal deformity. Results A total of 236 consecutive cases were identified spanning a 2-year period. Septoplasty specimens were sent for pathology evaluation in 76 (31%). The decision to send a specimen for histopathology was largely physician dependent. No cases yielded unexpected or significant pathology that changed management. The average total charges for septoplasty were $10,200 at our institution, with 2.2% of procedural charges accounting for pathology preparation and review, averaging $225. Nationally, this results in an estimated charged cost of $58.5 million. The Centers for Medicare and Medicaid Services (CMS) reimbursement for septoplasty pathology charges was $46 in 2018, accounting for 1.3% of hospital-based reimbursements and 2.2% of ambulatory center reimbursements. With CMS as a national model for reimbursement, $11.8 million is spent yearly for septoplasty histopathology. Given that CMS reimbursement is significantly lower than private insurers, national total reimbursement is likely considerably higher. Conclusion Routine pathology review of routine septoplasty specimens is unnecessary, unremarkable, and wasteful. Correlation of the patient’s presentation and intraoperative findings should justify the need for pathology evaluation. This value-based approach can offer significant direct and indirect cost savings. Level of evidence 4.

Metered-Dose Inhalers: Mouth Open or Closed?-Reply

JAMA ◽  
1994 ◽  
Vol 271 (4) ◽  
pp. 272
Author(s):  
Michael J. Tidd
Keyword(s):  
Metered Dose Inhalers ◽  
Metered Dose
Sign in / Sign up

Export Citation Format

Share Document